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In brief
Background and aims
This paper reviews what we have learned from the following four major national drug treatment
outcome studies:
UK
•NTORS (National Treatment Outcome Research Study).
US 
•DARP (the Drug Abuse Reporting Programme)
• TOPS (Treatment Outcome Prospective Study)
• DATOS (Drug Abuse Treatment Outcome Study).
Findings and main implications
Substantial reductions in illegal drug misuse and
other outcomes were found after treatment. 
Improved outcomes were also found for injecting
risk behaviours.
Most drug dependent clients were multiple
substance misusers and often had multiple
dependencies. To focus on single substance
disorders is outdated and misleading. 
Overdose remained a serious problem among drug
misusers with a greatly increased risk of mortality. 
Time in treatment and treatment completion
were found to be associated with better
treatment outcomes. Treatment effectiveness
may be increased through improved rates of
patient retention.
The reductions in crime levels provide substantial
and immediate cost savings for society. 
Methadone programmes achieved a range of 
improved client outcomes. 
Case-mix differences were found, with more
severely problematic drug misusers receiving
treatment in residential programmes.
Most drug dependent clients received more than
one episode of treatment. Little is known about
possible cumulative effects of multiple treatments,
or how separate and/or different treatment
episodes interact or interfere with each other. 
Drinking outcomes were often poor with many
clients continuing to drink heavily.
Treatment of drinking problems among drug
misusers should be strengthened.
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2DARP (Drug Abuse Reporting Programme1)
Commencing in 1968, DARP investigated four treatment types:
• methadone maintenance
• therapeutic communities
• outpatient drug-free services
• outpatient detoxification.
Data were collected from treatment entry until treatment termination on an 
initial sample of 44,000 clients at 52 treatment agencies. Follow-up data 
were available at one, two, and three years after treatment. Follow-up interviews
were conducted after treatment with over 6,000 patients in the first wave of
post-treatment follow-up interviews (on average, after six years). In 1982, a
second wave of follow-ups was conducted with a sample of about 700 people
approximately 12 years after admission to treatment. The programme also
looked at a comparison group which enrolled for, but never started, treatment.
TOPS (Treatment Outcome Prospective Study2)
This study was modelled closely on DARP and also provided data on clients
entering US drug treatment programmes. Setting out to assess short and long
term treatment outcomes, the first intake of data was collected in 1979. In this
case, the four treatment modalities investigated were:
• methadone maintenance
• detoxification
• residential
• outpatient drug-free programmes.  
TOPS involved almost 12,000 clients entering treatment in 41 addiction
treatment programmes across ten US cities. The sample was recruited in three
waves in 1979, 1980 and 1981. Interviews were conducted at the point of
admission to treatment as well as during treatment. Over 4,000 patients were
selected for post-treatment interviews, with samples followed up at three
months, one year, two years, and three to five years after treatment.   
Aims of the paper
This paper reviews what we have learned from the major national treatment outcome studies. 
Prospective treatment outcome studies have played an important role in improving our understanding of
treatment effectiveness. They provide information about drug misusers and their problems as well as the
nature of their involvement with treatment services. They also help us to understand the changes that
occur in drug misuse and other problem behaviours after treatment. 
Studies examined
The following major studies were considered:
3DATOS (Drug Abuse Treatment Outcome Study3) 
Initiated in 1989 as a continuation of NIDA’s (National Institute on Drug Abuse)
long-term investment in national treatment outcome studies, DATOS investigated
the links between patient outcome, treatment process and programme structure.
Looking at clients who entered treatment between 1991 and 1993, intake data
were collected on over 10,000 clients from 99 treatment programmes in 11 US
cities - both during treatment and 12 months after treatment. 
The four types of treatment programmes investigated were: 
• methadone maintenance
• short-term residential (hospital inpatient and chemical dependency)
• long-term residential (therapeutic community)
• outpatient drug-free treatment. 
NTORS (National Treatment Outcome Research Study4) 
Commissioned by a Department of Health Task Force in 1994, this study
recruited 1,075 clients from 54 treatment programmes during 1995. Forming 
the largest prospective longitudinal cohort study of treatment outcome for drug
misusers to be conducted in the UK, it investigated problem drug misusers 
in the following four treatment modalities throughout England:
• specialist inpatient treatment (residential)
• rehabilitation programmes (residential) 
• methadone maintenance (as a community-based treatment) 
• methadone reduction (as a community-based treatment).
An important feature of the studies that form the foundation of this paper is that
they investigated treatment outcomes in existing services under day-to-day
clinical circumstances. Such studies are rare – not only because of the high
financial costs involved, but also because of the degree of effort and
organisation required to implement, coordinate and sustain data collection
systems over a number of years. 
4Findings
Outcome measures
The main outcome measures across the treatment outcome studies are:
• substance misuse behaviour (including substance type, frequency and
quantity of use)
• health (psychological and physical health problems)
• social functioning (employment, accommodation and crime)
• harm (injecting and sharing injecting equipment).
These measures are similar to those in commonly used assessment instruments, 
such as:
• ASI (Addiction Severity Index) which assesses problem severity for drug and
alcohol misuse, medical, legal, employment, family/social and psychiatric
problems
• OTI (Opiate Treatment Index) which contains measures of drug misuse, HIV
risk-taking behaviour, social functioning, criminality, health status and
psychological adjustment.    
The selection of outcome measure(s) may lead to different findings and have
different implications.  The definition of relevant and priority outcomes may also
be made in different ways by individual clients, clinicians, treatment purchasers,
public health agencies and researchers.
Client outcomes
Client outcomes can be extremely variable.  Some individuals who become
drug-free following treatment stay that way, while some relapse. Others achieve
varying degrees of improvement regarding reduced frequency or quantity of use,
or reductions in drug-related problems.  Many fluctuate between improvement
and deterioration in terms of drug use, alcohol use, crime, social functioning,
and mental and physical health problems – but the trend is generally positive.  
Because drug addiction is associated with a wide range of other problems, it is
easy to construct a lengthy list of potential targets for treatment and evaluation.
Drug misuse outcomes
The most stringent criterion for treatment outcome is abstinence, and this was an
explicit treatment goal of the residential treatment programmes. Almost half (49
per cent) of the residential patients were abstinent from heroin after five years,
and the percentage of residential clients who were abstinent from all six illicit
target drugs increased from one per cent at intake, to 38 per cent after five
years. This is an encouraging finding considering that it is such a strict outcome
criterion and that it applies to such a severely problematic group of drug
misusers.
NTORS showed substantial reductions in a range of drug misuse behaviours,
including misuse of heroin and non-prescribed methadone and benzodiazepines.
For example, frequency of heroin use after one year was reduced to about half of
the intake levels – and remained at this lower level throughout the follow-up period.
Instances of injecting and sharing injecting equipment were also reduced over time.
Categories of drug misuse
Categorising drug misusers according to a single drug type does not reflect
contemporary patterns of drug use and abuse. The most frequently reported
drug problem among NTORS clients was heroin dependence, but the majority
of clients were multiple drug misusers.  
Terms implying single substance misuse - such as ‘heroin addict’ or ‘cocaine
user’ - can be misleading.  It is probably not adequate to classify drug takers
according to a primary or ‘main’ drug of preference, with other types of drugs
being seen as ‘secondary’. 
Patterns in drug misuse 
Since the 1960s, heroin has consistently been the most frequently reported
‘main’ problem drug among drug misusers in treatment in the UK. However,
heroin use almost never occurs in isolation. Cocaine, amphetamines and
benzodiazepines are also widely used by drug misusers seeking treatment for
heroin dependence. Almost two thirds of the NTORS sample were using three
or more substances before admission to treatment, and more than a third was
using stimulants on a frequent basis5. The most commonly used stimulant
among drug misusers seeking treatment for heroin dependence was crack
cocaine. 
Crack misuse
Abstinence from crack increased, and there were reductions in the frequency of
crack misuse between intake and one year. However, these improvements
appeared to diminish over time. At the five year follow-up, the overall rates for
crack use and the frequency of use had returned to approximately the same
levels as at intake. 
This apparently poor outcome for crack cocaine misuse requires careful
interpretation. While results appear to show no change in rates of use at five
years, the overall figures disguise different patterns of crack misuse among
those who were using it, and those who were not, during the period prior to
intake. Levels among those misusing crack at intake dropped by more than half
at all follow-up points. In contrast, there was a gradual increase in the use of
this drug among those who were not misusing crack at intake. 
The results regarding the misuse of crack cocaine should therefore be put
down to the initiation of crack misuse among those who were not using this
drug at intake6 – and not a tendency to relapse to pre-admission patterns
among those already using this drug at intake.
Injecting risk behaviours
Most drug treatment services provide interventions targeted at injecting risk
behaviours. NTORS showed significant reductions in injecting and the sharing
of injecting equipment among both the residential and the methadone clients.
The overall rate of sharing of injecting equipment fell to less than five per cent -
approximately a quarter of intake levels. 
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6Alcohol misuse problems
Heavy drinking – especially alcohol dependence – is an important and often
under-rated problem in drug misuse treatment. It may aggravate other drug-
related and health problems, and also adversely affect treatment outcomes. 
There is wide variation in drinking patterns among drug misusers. Of the
NTORS sample, about a third had abstained from alcohol throughout the three
month period prior to treatment. This abstinence rate is much higher than for
age-matched samples from the non drug misusing population. However, many
of those who were drinkers reported problematic patterns of drinking. Nearly a
fifth was co-dependent on alcohol and regularly drinking excessively (that is,
on average, the equivalent of a bottle of spirits per day). 
NTORS clients who were severely co-dependent on alcohol were found to be
more likely to have had drug-related problems such as abscesses, vein
scarring, and overdoses. 
Drinking outcomes
Drinking outcomes after drug misuse treatment were often poor, with many
drinkers making little or no change in their pre-treatment drinking7. With the
exception of a fluctuation in frequency of drinking (in the form of a reduction at
one year followed by an increase at two year follow-up), there was no
reduction in drinking among clients on residential treatment programmes.
Among the methadone clients, no change was found at any point during the
follow-up period. With clients from both settings, alcohol consumption was no
different from intake levels.  
Even where there were reductions in alcohol misuse, these were often
unsatisfactory in that they consisted of reductions from very heavy to heavy –
as opposed to moderate – levels of drinking. Heavy drinking represents a
serious threat to the health of this group, especially as so many have liver
disease and impaired liver function, often as a result of hepatitis C infection.
Drinking problems often receive insufficient attention in the treatment of illicit
drug misusers.  Drug misusers and clinical staff may either deliberately or
unintentionally focus upon what is perceived to be the ‘main’ illicit problem
drug – typically, heroin or cocaine. By doing so they may neglect or minimise
the misuse of other substances.  
The continued heavy drinking of so many clients after treatment contrasts with
the widespread changes and substantial improvements found within the same
group in terms of reduced use of most illicit drugs.  Furthermore, the extent
and severity of their heavy drinking, both before and after treatment, points to
the need to develop programmes and interventions which are specifically
designed to tackle alcohol-related problems in this patient group.  
Poor drinking outcomes represent an area of weakness requiring urgent
attention by drug misuse treatment services, especially by methadone
treatment services. Treating drug and alcohol dependent clients in separate
treatment services can be problematic for clients who are dually dependent
upon both drugs and alcohol. Separate treatment systems can lead to a lack
of liaison between drug and alcohol dependence services and placing the
burden of accessing the different services upon the clients, who are often
poorly equipped for this task.
Psychological health
Improvement in psychological health and functioning is an important treatment
goal for drug misusers. At intake to treatment, NTORS clients reported many
symptoms, with about one in five having previously received treatment for a
psychiatric health problem other than substance misuse. Anxiety and
depression were common. Rates of depression and suicide were particularly
high among women drug misusers.
Reductions in psychological symptoms were found after one year among both
residential and methadone clients. Among residential clients, there was a
further drop in symptom levels after the one year follow-up. These were lower
than intake levels at the final five year follow-up.  
These overall improvements suggest that gains in mental health are achieved
after treatment in existing services. At the same time, the severity of psychiatric
disorder has been found to be related to poorer treatment outcomes. The high
prevalence of psychiatric symptoms among drug misusers seeking treatment
indicates the importance of conducting as thorough a psychiatric assessment
as the context of routine clinical practice allows.
Overdose and mortality
Drug overdose is one of the most frequent causes of death among drug
misusers. The annual mortality rate of the NTORS sample was 1.2 per cent.
This is about six times higher than for a general, age-matched population.
Heroin is frequently implicated in fatal overdoses as a result of respiratory
depression. However, overdoses commonly attributed to the use of opiates are
seldom due to the use of opiates alone. In the majority of cases, more than one
drug was detected. Indeed, a single substance was found at postmortem in
only about one in five of the cases.  In more than half of the overdose deaths,
three or more different drugs were detected. The most common drug
combinations associated with death involved opiates and alcohol, opiates and
benzodiazepines, or a mixture of all three of these drugs8.
In addition to overdoses and deaths resulting from blood borne diseases, 
the risk of death is also affected by environmental factors. Ten per cent of the
NTORS clients were homeless or not in stable accommodation at intake. Results
showed that homelessness also increased the risk of mortality, emphasising the
need to obtain adequate accommodation for drug misusers.
Crime 
The reductions in crime are among the more striking findings from NTORS.
The NTORS sample reported committing a very large number of acquisitive
crimes during the 90 day period prior to treatment intake. The most common
type of offence, both in terms of total number of crimes and in terms of
percentages of clients committing that offence, was shoplifting. After treatment,
there were substantial reductions both in the numbers of crimes committed
and in the percentage of clients engaged in acquisitive crime. At one year,
acquisitive crimes were reduced to one third of intake levels, and involvement
in crime was reduced to about half of intake levels9.
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8These reductions in crime were maintained through to the five year follow-up.
Reductions were found both for acquisitive crimes and for drug selling crimes.
Overall, both types of crime were reduced to about a quarter of the levels at
intake. Criminality on the scale reported at intake represents a formidable
social and economic problem. These results point to the role that treatment
interventions can play in helping to tackle crime among drug misusers. The
reductions in crime provide substantial and immediate benefits to society
through the reduced economic costs of crime, and they provide equally
important, if less tangible, benefits through the reduced levels of distress
caused to victims.
The impact of different modalities 
NTORS found generally good responses to treatment in both residential and
community settings across the four treatment modalities. Those in the
residential modalities reported more serious problems at intake than the clients
in the two community treatments. Residential rehabilitation clients presented
with the longest heroin careers, and were more likely to be polydrug users.
They were also more likely to be dually dependent upon alcohol and drugs,
and to have shared injecting equipment. Additionally they were more likely to
have been involved in crime, and had been arrested more times than other
clients. However, little is known about how most effectively to allocate
individual clients to one or other treatment setting. 
Treatment in a residential setting provides the potential for an intensive and
comprehensive treatment programme. It can provide a place of safety, and
psychological and social respite for clients by removing them from their drug
taking environments, and by supporting drug-free functioning.  It may also be
useful for clients who do not respond to less intense interventions. With this in
mind, it seems appropriate that the more severely problematic drug misusers
receive treatment in the more intensive programmes. 
Hospital settings permit a high level of medical supervision and safety for
clients needing intensive psychiatric care.  This makes it appropriate for the
treatment of clients with complex dual diagnosis disorders.  
One of the most conspicuous differences between treatment in an inpatient or
an outpatient setting is cost. However, discussion of treatment costs are
misleading if not informed by, and adjusted for, evidence of effectiveness.
This is especially important where there are marked differences in patient
characteristics and problems in different settings, or where different treatments
lead to different outcomes.  
Changes in behaviour after treatment have often been attributed in a 
non-specific manner to therapeutic and cognitive processes which may have
occurred during and after treatment. For some time there has been broad
agreement that we need to identify those treatment factors and treatment
processes which affect outcomes. 
Among the treatment process concepts which have been identified as of
potential importance are ‘treatment dose’, ‘therapeutic relationship’ and
‘treatment engagement’. If treatment is to produce improved outcomes, clients
should stay for long enough to be exposed to, and to participate in, treatment
of sufficient quality and intensity to bring about change. 
Time in treatment  
Better treatment outcomes were found to be associated with time in treatment
and whether treatment is completed. In NTORS, this treatment duration effect
was found both for treatments in residential settings and for methadone
maintenance. It is thought that achieving higher client retention rates is a
significant factor in increasing the effectiveness of treatment services.
In several instances, the planned duration of some inpatient programmes was
shorter than minimum thresholds identified as associated with improved
outcomes10. In some cases the programme duration was less than 28 days. It is
a matter for concern that this falls below the minimum duration suggested by
this analysis – and may be too brief to provide improved outcomes.
Unfortunately, both in the UK and other countries, many decisions about
treatment duration appear to be driven by financial pressures rather than by
evidence about treatment effectiveness. The US studies reviewed for the
purposes of this paper indicated that the two elements under the most threat
were programme duration and provision of residential treatment.
Methadone maintenance treatment (MMT) and 
methadone reduction treatment (MRT)
Clients receiving both MMT and MRT showed improvements in a range of
problem behaviours after treatment. However, more detailed analyses identified
problems regarding MRT, particularly treatment integrity (i.e. was treatment
delivered as intended). If you include all those for whom treatment was
planned, the majority of MMT clients were found to receive maintenance,
whereas only about one third of MRT clients actually received methadone
reduction as planned. Instead, they received a form of methadone maintenance
(stable doses over a prolonged period). Where it was intended for clients to
receive MRT, the treatment was frequently not delivered in this form11.    
Where MRT was delivered as intended, it was associated with poor outcomes.
Methadone dose is an important treatment factor – and in MMT higher doses
were associated with better outcomes than lower doses. MRT clients were more
likely than MMT clients to receive low doses both at the beginning and during
the course of treatment.  Eighty per cent of those allocated to MRT were
prescribed a starting dose of 60mg or less, and 15 per cent received a starting
dose of less than 30mg.  
MMT clients were more likely to remain in treatment at all follow-up points.  
To some extent, this is to be expected since, some MRT clients may have
completed their treatment programmes. However, this was not reflected in any
improved outcomes among this client sample. Nor is it consistent with the
finding that many intended MRT programmes were extended over timescales
well beyond what might be regarded as reasonable. This is borne out by the
fact that some 50 per cent of the MRT clients were still in their index treatment
after one year, and almost a third were still in treatment after two years. 
NTORS raised other doubts about the effectiveness of MRT. For clients who
received MMT, improved outcomes were associated with higher methadone
doses and retention in treatment. For the clients who received MRT, the only
treatment factor which was found to be (negatively) associated with outcome
was the percentage of reducing doses which was linked to more frequent
heroin use at two year follow-up. A high percentage of reducing doses is
indicative of a more rapid reduction schedule. The more rapidly methadone
was reduced, the worse the heroin misuse outcomes.  
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More severely dependent clients achieved better heroin use outcomes when
they received MMT rather than MRT. When allocating clients to either MMT or
MRT, NTORS recommended that more severely opiate dependent clients
should be offered MMT as the preferred outpatient treatment.
The bigger picture
Interventions taking place during treatment are just part of a much wider range
of factors that can influence outcome. In many cases, treatment may be neither
the most important nor the most powerful influence upon outcome.
Environmental supports and stresses can influence outcomes. Peer and family
relationships, unemployment and living arrangements can all have an important
effect. The gains produced by an effective treatment programme can be
undermined or neutralised by adverse social and environmental factors.
Nonetheless, treatment interventions can seek to develop and strengthen
coping responses that increase the probability of improved treatment outcomes
and this can be further supported by aftercare services12.
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